+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Auranofin Market by Indication (Oncology, Rheumatoid Arthritis), Therapeutic Class (DMARDS, Gold Compounds), Distribution Channel, End User, Dosage Strength - Global Forecast 2025-2030- Product Image
Auranofin Market by Indication (Oncology, Rheumatoid Arthritis), Therapeutic Class (DMARDS, Gold Compounds), Distribution Channel, End User, Dosage Strength - Global Forecast 2025-2030- Product Image
Sale

Auranofin Market by Indication (Oncology, Rheumatoid Arthritis), Therapeutic Class (DMARDS, Gold Compounds), Distribution Channel, End User, Dosage Strength - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082722
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Auranofin market is entering a pivotal phase, with therapeutic innovation, evolving regulatory frameworks, and new supply chain models shaping its opportunities in both oncology and autoimmune care. Senior leaders need clear, actionable intelligence to navigate this complex landscape and align strategies with emerging stakeholder priorities.

Market Snapshot: Auranofin Market Size and Growth

In the latest industry analysis, the Auranofin market grew from USD 218.99 million in 2024 to USD 230.02 million in 2025. The sector is set to progress further at a CAGR of 4.85%, driven by ongoing advances in pharmaceutical repurposing and therapeutic development, with a forecasted value of USD 291.00 million by 2030. These growth dynamics stem from the compound’s expanding clinical portfolio and its renewed relevance among both established and emerging treatment regimens.

Scope & Segmentation

This comprehensive report provides a deep dive into the evolving dimensions of the Auranofin market. Key segmentation areas include:

  • Indications: Coverage across leukemia, lymphoma, moderate rheumatoid arthritis, and severe rheumatoid arthritis, reflecting the molecule's utility in oncology and autoimmune disorders.
  • Therapeutic Classes: Analysis encompasses categories such as DMARDs (biologics, conventional, targeted synthetic) as well as gold compounds for differentiated therapy positioning.
  • Distribution Channels: Focus spans hospital pharmacies, online pharmacies, and retail pharmacies to capture diverse access pathways.
  • End Users: Examines uptake among home care settings, hospitals, and specialty clinics as care decentralizes.
  • Dosage Strengths: Reviews clinical implications and accessibility of both 3 mg and 6 mg formulations.
  • Regions: Granular insights are provided into the Americas, Europe, Middle East & Africa, and Asia-Pacific, including leading submarkets such as the US, Canada, Brazil, Germany, China, India, and others.
  • Leading Companies: Assesses strategic moves by Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Viatris Inc, Amneal Pharmaceuticals LLC, Fresenius Kabi AG, and others.

Key Takeaways for Senior Decision-Makers

  • Expansion beyond initial rheumatoid arthritis management is positioning Auranofin as a multi-indication contender, with concerted research into oncology subtypes such as leukemia and lymphoma.
  • Clinical trials emphasize dosage optimization and personalized treatment pathways, integrating insights from both biologic and synthetic protocols.
  • Enhanced distribution networks now include home care and digital channels, broadening patient access and supporting decentralized treatment trends.
  • Collaborations between academic institutions and biotech innovators foster exploration of translational biomarkers and patient stratification, accelerating clinical validation in new therapeutic areas.
  • Market segmentation reveals tailored opportunities, as diverse patient cohorts and end-user needs drive differentiated dosing and access models.
  • The flexible adoption of digital health solutions and resilient supply chains supports operational agility for stakeholders facing fluctuating regulatory and demand environments.

Auranofin Market: Tariff Impact and Supply Chain Realignment

Upcoming adjustments to US tariffs in 2025 are anticipated to reshape Auranofin’s supply chain and pricing structures. Increased duties on imported intermediates may drive up manufacturing costs, particularly for firms dependent on gold salt imports or specialized reagents. Stakeholders, from suppliers to pharmacies, should consider strategic sourcing, localized production investments, and agile procurement protocols to mitigate risk. Value-based contracts and alternative channel alignment can help sustain patient access despite evolving cost frameworks.

Methodology & Data Sources

This analysis employs a robust mixed-method approach, integrating primary interviews with stakeholders—such as clinicians, distribution partners, and CROs—and in-depth secondary research from peer-reviewed literature, regulatory filings, and proprietary data sets. Data triangulation ensures accuracy and relevance, further validated through expert workshops and comparative policy review across major agencies.

Why This Report Matters

  • Enables senior leaders to anticipate regulatory and clinical paradigm shifts, aligning business planning with future market contours.
  • Delivers clarity on region-specific opportunities and risks, supporting international expansion and coordinated go-to-market strategies.
  • Equips stakeholders with actionable insights for R&D, supply chain resilience, and tariff response to ensure business continuity and value creation.

Conclusion

As the Auranofin market continues to diversify and expand, strategic foresight rooted in robust data is essential. This report offers a foundation for informed decision-making, operational resilience, and long-term market leadership.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising clinical evidence for auranofin repurposing in oncology indications such as ovarian and gastric cancers
5.2. Emergence of generic auranofin formulations driving price drops and wider market access
5.3. Strategic partnerships between biotech firms and academic centers for auranofin research in neurodegenerative diseases
5.4. Regulatory pathways and expedited approvals for repurposed auranofin in rare disease indications
5.5. Real-world evidence studies highlighting auranofin safety and efficacy in off-label antimicrobial applications
5.6. Supply chain challenges and raw gold sourcing impact on auranofin manufacturing costs and timelines
5.7. Investor interest surge following positive phase II trial results of auranofin in rheumatoid arthritis refractory patients
5.8. Advances in nanoparticle formulations to enhance auranofin targeted delivery and bioavailability profiles
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Auranofin Market, by Indication
8.1. Introduction
8.2. Oncology
8.2.1. Leukemia
8.2.2. Lymphoma
8.3. Rheumatoid Arthritis
8.3.1. Moderate
8.3.2. Severe
9. Auranofin Market, by Therapeutic Class
9.1. Introduction
9.2. DMARDS
9.2.1. Biologics
9.2.2. Conventional
9.2.3. Targeted Synthetic
9.3. Gold Compounds
10. Auranofin Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Auranofin Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Auranofin Market, by Dosage Strength
12.1. Introduction
12.2. 3mg
12.3. 6mg
13. Americas Auranofin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Auranofin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Auranofin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Teva Pharmaceutical Industries Ltd
16.3.2. Sandoz International GmbH
16.3.3. Viatris Inc
16.3.4. Amneal Pharmaceuticals LLC
16.3.5. Fresenius Kabi AG
16.3.6. Aurobindo Pharma Ltd
16.3.7. Dr. Reddy’s Laboratories Ltd
16.3.8. Apotex Inc
16.3.9. Hi-Tech Pharmacal Co., Inc
16.3.10. Sagent Pharmaceuticals Inc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. AURANOFIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. AURANOFIN MARKET: RESEARCHAI
FIGURE 26. AURANOFIN MARKET: RESEARCHSTATISTICS
FIGURE 27. AURANOFIN MARKET: RESEARCHCONTACTS
FIGURE 28. AURANOFIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. AURANOFIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL AURANOFIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. CANADA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 102. CANADA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 103. CANADA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 104. CANADA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 105. CANADA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 106. CANADA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 107. CANADA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 108. CANADA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 109. CANADA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. CANADA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. CANADA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. CANADA AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. CANADA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 114. CANADA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 115. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. MEXICO AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 118. MEXICO AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 119. MEXICO AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 120. MEXICO AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 121. MEXICO AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. MEXICO AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. MEXICO AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. MEXICO AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. MEXICO AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 130. MEXICO AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 197. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. GERMANY AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 200. GERMANY AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 201. GERMANY AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 202. GERMANY AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 203. GERMANY AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. GERMANY AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. GERMANY AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. GERMANY AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. GERMANY AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 212. GERMANY AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 213. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. FRANCE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 216. FRANCE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 217. FRANCE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 218. FRANCE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 219. FRANCE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. FRANCE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. FRANCE AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. FRANCE AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. FRANCE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 228. FRANCE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 245. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. ITALY AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 248. ITALY AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 249. ITALY AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 250. ITALY AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 251. ITALY AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 252. ITALY AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 253. ITALY AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 254. ITALY AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 255. ITALY AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. ITALY AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. ITALY AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. ITALY AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. ITALY AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 260. ITALY AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 261. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. SPAIN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 264. SPAIN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 265. SPAIN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 266. SPAIN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 267. SPAIN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. SPAIN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. SPAIN AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. SPAIN AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. SPAIN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 276. SPAIN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 325. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 326. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 327. DENMARK AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 328. DENMARK AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 329. DENMARK AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 330. DENMARK AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 331. DENMARK AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 332. DENMARK AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 333. DENMARK AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 334. DENMARK AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 335. DENMARK AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 336. DENMARK AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 337. DENMARK AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 338. DENMARK AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 339. DENMARK AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 340. DENMARK AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 341. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 342. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 343. NETHERLANDS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 344. NETHERLANDS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 345. NETHERLANDS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 346. NETHERLANDS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 347. NETHERLANDS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 348. NETHERLANDS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 349. NETHERLANDS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 350. NETHERLANDS AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 351. NETHERLANDS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 352. NETHERLANDS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 353. NETHERLANDS AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 354. NETHERLANDS AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 355. NETHERLANDS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 356. NETHERLANDS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 357. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 358. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 359. QATAR AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 360. QATAR AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 361. QATAR AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 362. QATAR AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 363. QATAR AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 364. QATAR AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 365. QATAR AURANOFIN MARKET SIZE, BY DMARDS, 2018-2024 (USD MILLION)
TABLE 366. QATAR AURANOFIN MARKET SIZE, BY DMARDS, 2025-2030 (USD MILLION)
TABLE 367. QATAR AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 368. QATAR AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 369. QATAR AURANOFIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 370. QATAR AURANOFIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 371. QATAR AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 372. QATAR AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 373. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 374. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 375. FINLAND AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 376. FINLAND AURANOFIN MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 377. FINLAND AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 378. FINLAND AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 379. FINLAND AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (U

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Auranofin market report include:
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Viatris Inc
  • Amneal Pharmaceuticals LLC
  • Fresenius Kabi AG
  • Aurobindo Pharma Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Apotex Inc
  • Hi-Tech Pharmacal Co., Inc
  • Sagent Pharmaceuticals Inc

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 230.02 Million
Forecasted Market Value ( USD ) by 2030 $ 291 Million
Compound Annual Growth Rate4.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Auranofin (CAS 34031-32-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Auranofin (CAS 34031-32-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Rheumatology Therapeutics Market by Therapeutic Class (Conventional Dmards, Il-6 Inhibitors, Jak Inhibitors), Molecule Type (Biologics, Biosimilars, Small Molecules), Indication, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2030 - Product Image

Rheumatology Therapeutics Market by Therapeutic Class (Conventional Dmards, Il-6 Inhibitors, Jak Inhibitors), Molecule Type (Biologics, Biosimilars, Small Molecules), Indication, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Rheumatology Therapeutics - Global Strategic Business Report - Product Image

Rheumatology Therapeutics - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Rheumatoid Arthritis Treatment - Global Strategic Business Report - Product Image

Rheumatoid Arthritis Treatment - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From

About the Auranofin Market

Auranofin is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is an oral gold-based medication that works by suppressing the immune system and reducing inflammation. Auranofin is a relatively new drug, having been approved by the FDA in 1985. It is generally well-tolerated, with few side effects. Auranofin is used in combination with other medications to treat immune disorders. It is often prescribed in combination with non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). Auranofin is also used to treat other conditions, such as lupus and Sjogren's syndrome. The Auranofin market is a growing one, with many companies offering the drug. Some of the companies in the market include Mylan, Teva Pharmaceuticals, and Sandoz. Other companies, such as Pfizer, Merck, and Novartis, also offer Auranofin in some countries. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.